Tekla Life Sciences Investors
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Tekla Life Sciences Investors's past years’ income statements indicate that its last revenue has increased compared to the previous period by 269% to $86,685,230. The net income raised on $85,296,459 and profit margin reached 98%. Total operating expenses were $86,685,230.

Profit Margin

Tekla Life Sciences Investors (NYSE:HQL): Profit margin
2015 1.32M 40.49M 3062.09%
2016 1.43M -11.91M -828.8%
2017 69.81M 68.55M 98.2%
2018 29.82M 28.66M 96.12%
2019 -69.34M -70.47M 101.64%
2020 124.08M 123.05M 99.17%
2021 65.68M 64.53M 98.24%
2022 -103.25M -104.60M 101.31%
2023 23.52M 22.35M 95.02%
2024 86.68M 85.29M 98.4%

HQL Income Statement (2015 – 2024)

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue
Revenue
86.68M23.52M-103.25M65.68M124.08M-69.34M29.82M69.81M1.43M1.32M
Cost of revenue
05.24M5.54M6.07M5.20M5.00M4.77M4.60M4.54M5.64M
Gross profit
86.68M18.27M-108.79M59.61M118.87M-74.34M25.05M65.20M-3.11M-4.32M
Operating exp.
Research and development
00-313-10100
Selling and marketing
0000000000
Total operating expenses
86.68M23.52M1.35M1.15M1.02M1.13M1.15M1.25M678.80K39.17M
Operating income
0-5.24M-104.60M64.53M123.05M-70.47M-3.60M-3.87M-3.79M-4.72M
Other income (expenses), net
85.29M27.59M2.42K-7.83K5.20M-4.68K32.27M72.73M-8.12M45.22M
Income before tax
85.29M22.35M-104.60M64.53M123.05M-70.47M28.66M68.55M-11.91M40.49M
Income tax expense
00-2.98M-4.14M-2.12M-2.88M13045.22M
Net income
85.29M22.35M-104.60M64.53M123.05M-70.47M28.66M68.55M-11.91M40.49M
Earnings per share
Basic EPS
00.79-4.072.665.16-3.041.283.21-0.572.06
Diluted EPS
00.79-4.072.665.16-3.041.233.21-0.572.06